What is the current stock price of Newron Pharmaceuticals S.p.A. (NWPHF)?

As of the latest market data, Newron Pharmaceuticals S.p.A. (NWPHF) is trading at $20.00. The stock has seen a loss of 0.00% today.

Does Newron Pharmaceuticals S.p.A. (NWPHF) pay a dividend?

Based on current data, Newron Pharmaceuticals S.p.A. does not have a confirmed active dividend policy.

What is the market cap of Newron Pharmaceuticals S.p.A.?

The current market capitalization of Newron Pharmaceuticals S.p.A. (NWPHF) is approximately unavailable.

NWPHF

Newron Pharmaceuticals S.p.A.·Healthcare

20.00

0.000%(+0.00)

Close Price

Last Updated: — ET

52W L: $9.3652W H: $20.00

NWPHF NEWS

seekingalpha.com

Mar 24

Newron Pharmaceuticals S.p.A. (NWPHF) Q4 2025 Earnings Call Transcript

businesswire.com

Mar 24

Newron Presents 2025 Financial Results and Provides 2026 Outlook

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron today announced its financial results and operational highlights for the business year ended Dec. 31, 2025, and provided an outlook for 2026.

businesswire.com

Mar 20

Newron to Present at the 2026 Annual Congress of the Schizophrenia International Research Society (SIRS)

MILAN & MORRISTOWN, N.J.--(BUSINESS WIRE)---- $NWRN #schizophrenia--Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it will take part in a workshop and present three posters at the upcoming SIRS 2026 Annual Congress taking place March 25-29, 2026, at the exhibition and congress area Firenze Fiera in Florence, Italy. Workshop Wednesday,.

Company Profile

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2017-08-30

Beta

0.78

Websitewww.newron.com↗